This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Kestutis Rucinskas Vytautas Sirvydis Permission Requests Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Malickaite, R. Articles by Sirvydis, V. Search for Related Content PubMed PubMed Citation Articles by Malickaite, R. Articles by Sirvydis, V.

Sensitisation and post-transplant course after the implantation of ventricular assist device

^a Vilnius University, Santariskiu 2, LT-08661, Vilnius, Lithuania
^b Vilnius University Hospital Santariskiu Klinikos, Vilnius, Lithuania

*Corresponding author. Tel.: +370 5 2365186; fax: +370 5 2365242.

E-mail address: radvile.malickaite{at}santa.lt (R. Malickaite).

The purpose of this study was to evaluate sensitisation, occurring because of bridging with VAD, and development of rejection episodes after transplantation in selected groups of patients using triple drug immunosuppression, without induction or desensitisation therapy. Sensitisation using standard complement dependent cytotoxicity was tested in 16 patients awaiting cardiac transplantation before VAD placement, one month post-implantation and on a six-monthly basis later on. Long-term (955±998 days) post-transplant course of six transplanted post-VAD patients was compared with 19 non-bridged recipients (follow-up time 1425±1273 days) of the same age. One-third of VAD recipients had developed anti-HLA antibodies one month post-implantation; 4/16 patients were sensitised six months after implantation. No de novo sensitisation development was revealed in VAD group post-transplantation. All sensitised patients independent of VAD placement underwent graft rejection episodes. Only 1 of 6 VAD recipient was treated because of grade 2R rejection, compared to 6/19 in the non-bridged group, P=0.63. None of the patients had failed because of early graft rejection. In conclusion, VAD devices used in our centre cause low level risk for anti-HLA antibodies development. There were no differences in survival due to immunologic reasons between VAD bridged and non-bridged patients.

Key Words: Ventricular assist devices; Transplantation; Sensitisation